Skip to Content
Merck
All Photos(1)

Documents

Y0001288

Salbutamol sulfate for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Salbutamol hemisulfate salt, α1-[(tert-Butylamino)methyl]-4-hydroxy-1,3-benzenedimethanol hemisulfate salt, Albuterol sulfate

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C13H21NO3 · 0.5H2SO4
CAS Number:
Molecular Weight:
288.35
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

albuterol, salbutamol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

SMILES string

OS(O)(=O)=O.CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.CC(C)(C)NCC(O)c2ccc(O)c(CO)c2

InChI

1S/2C13H21NO3.H2O4S/c2*1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15;1-5(2,3)4/h2*4-6,12,14-17H,7-8H2,1-3H3;(H2,1,2,3,4)

InChI key

BNPSSFBOAGDEEL-UHFFFAOYSA-N

Gene Information

human ... ADRB2(154)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Salbutamol sulfate for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Pictograms

Health hazardExclamation mark

Signal Word

Warning

Hazard Statements

Hazard Classifications

Carc. 2 - Repr. 2 - Skin Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

B Padhukasahasram et al.
The pharmacogenomics journal, 14(4), 365-371 (2014-01-15)
Inhaled short-acting beta-agonist (SABA) medication is commonly used in asthma patients to rapidly reverse airway obstruction and improve acute symptoms. We performed a genome-wide association study of SABA medication response using gene-based association tests. A linear mixed model approach was
Dwight D Koeberl et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 28(5), 2171-2176 (2014-01-21)
Effective dosages for enzyme replacement therapy (ERT) in Pompe disease are much higher than for other lysosomal storage disorders, which has been attributed to low cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle. We have previously demonstrated the benefit of increased
Helgo Magnussen et al.
The New England journal of medicine, 371(14), 1285-1294 (2014-09-10)
Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored.
Tianwen Lai et al.
BMC pulmonary medicine, 15, 1-1 (2015-01-13)
YKL-40 is also called chitinase-3-like-1 (CHI3L1) protein and may be a marker for asthma. The aims of the present study were to investigate whether serum YKL-40 levels are stable or decreased in patients with asthma after appropriate treatment and to
Juliet M Foster et al.
The Journal of allergy and clinical immunology, 134(6), 1260-1268 (2014-07-27)
Poor adherence contributes to uncontrolled asthma. Pragmatic adherence interventions for primary care settings are lacking. To test the effectiveness of 2 brief general practitioner (GP)-delivered interventions for improving adherence and asthma control. In a 6-month cluster randomized 2 × 2

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service